Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

January Podcast: Most Notable Stories Of 2014

This article was originally published in The Pink Sheet Daily

Executive Summary

Biosimilars, FDA's breakthrough designation, and oncology strategies were among topics that drew the greatest reader interest this past year. Our latest "Pinkcast" recaps some key stories, traces subsequent developments, and notes key actions to watch for in 2015.

You may also be interested in...



Sanofi Board Forces CEO Chris Viehbacher to Resign Amid Lantus Woes

Sanofi announced that Christopher Viehbacher has resigned as CEO after its board voted unanimously to remove him. The drama comes amid serious worries over the group’s cash cow medicine, Lantus.

FDA Changes Own Tweets To Match Industry Guidance

PhRMA says agency’s previous tweets on drug approvals set reasonable standards, and wants firms to be able to adopt format that FDA had used.

FDA Expecting 10 Biosimilar Applications Submitted By End Of FY 2015

The agency says it expects to receive three biosimilar marketing applications in fiscal year 2014 and another seven in FY 2015, as well as much more in program revenue.

Related Content

Topics

UsernamePublicRestriction

Register

LL016481

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel